Research programme: rheumatoid arthritis antibody therapies - DebiopharmAlternative Names: Anti-CD44vRA antibody; Debio-0618
Latest Information Update: 12 Aug 2010
At a glance
- Originator Debiopharm
- Class Antibodies
- Mechanism of Action CD44 antigen inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 12 Jun 2007 Preclinical trials in Rheumatoid arthritis in Switzerland (Parenteral)